Naprod Life Sciences’ manufacturing facility at MIDC Tarapur, Boisar, Maharashtra, has had its Good Manufacturing Practice (GMP) certification renewed by ANVISA, Brazil’s national health surveillance agency (Agência Nacional de Vigilância Sanitária), the company confirmed in January 2026. The renewal was reported by Pharma India Magazine.
ANVISA GMP certification is a prerequisite for any facility supplying finished pharmaceutical products into Brazil. The agency conducts periodic on-site and documentation-based reassessment of manufacturing sites before extending certification, covering quality systems, sterile processing controls, and batch documentation against Brazilian regulatory standards. A lapsed or withdrawn certification would suspend a site’s eligibility to support product registrations in the market.
Why it matters for market access
Brazil is the largest pharmaceutical market in Latin America and a founding member of Mercosur, the regional trade bloc that also includes Argentina, Paraguay, and Uruguay. For an export-oriented sterile injectables manufacturer, an active ANVISA GMP certificate is the gating requirement behind every import registration and dossier filed for the market — it does not itself constitute approval of any individual product, but no product registration can proceed or remain valid at a site without it. The January 2026 renewal keeps Naprod’s existing Brazil-bound product registrations in force and keeps the Tarapur site eligible to support new dossier filings into the market.
The facility behind the certificate
The Tarapur site is Naprod’s principal sterile manufacturing facility, producing oncology, anesthesia, and critical-care injectables in both lyophilized and liquid form. Company-reported capacity for the site’s oncology lines stands at approximately 3.5 million lyophilized units and 3 million liquid units annually (figures pending confirmation), alongside general (non-oncology) lyophilized and liquid injectable lines. These are the product families qualified for supply into ANVISA-regulated trade.
Part of a broader regulatory register
The ANVISA renewal sits alongside Naprod’s existing register of international manufacturing certifications for the Tarapur site, which includes EU-GMP, WHO-GMP, INVIMA (Colombia), the UAE Ministry of Health, and NHRA Bahrain — a spread that supports export activity across Europe, Latin America, the Middle East, and other regulated markets. Each certificate is issued and maintained independently by its issuing authority, with its own renewal cycle and scope of coverage; Naprod’s Quality & Regulatory register lists validity status and issuing bodies for each as they are confirmed.
What this means for distributors and partners
For import registration holders, distributors, and contract partners sourcing sterile oncology injectables for the Brazilian market, an active ANVISA GMP certificate at the manufacturing site is typically a standing condition of the underlying supply agreement, not a one-time check performed at onboarding. Regulatory affairs teams filing or maintaining ANVISA dossiers can reference the January 2026 renewal date when updating site-certification documentation submitted alongside product registrations. As with all of Naprod’s regulatory certifications, verification of current status should be confirmed directly against ANVISA’s own published register rather than through secondary sources.
Trade coverage of the renewal appeared in Pharma India Magazine, an industry publication tracking Indian pharmaceutical manufacturing and regulatory developments. Naprod’s own Quality & Regulatory pages will reflect the updated validity window for the ANVISA certificate as documentation is finalized.
No claims regarding the safety or efficacy of any product are made or implied by this certification; ANVISA GMP status pertains solely to the manufacturing site’s quality systems and process controls.